Summaries of health policy coverage from major news organizations
FDA Approves Roche’s Combination Hepatitis C Treatment for Patients Co-Infected With HCV, HIV
FDA on Friday approved Roche's combination hepatitis C treatment for patients co-infected with HCV and HIV, the AP/Forbes.com reports (AP/Forbes.com, 2/25). The two drugs, called Pegasys and Copegus, already are FDA approved to treat chronic hepatitis C infections in patients without HIV (Kaiser Daily HIV/AIDS Report, 9/7/04). The combination HCV therapy is the first to receive approval for use in HIV-positive patients, for whom hepatitis is a leading cause of death (AP/Forbes.com, 2/25). About 30% of HIV-positive patients in the U.S. also have hepatitis C, Reuters reports (Reuters, 2/28). "For the first time, the 300,000 Americans who are co-infected with hepatitis C and HIV have an FDA-approved hepatitis C treatment option. This is a very important advance for the HIV community," Jeffrey Smith, director of clinical research for the American Foundation for AIDS Research, said (Roche release, 2/28).
This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.